NeuroSense Therapeutics Ltd. (NRSN)
NASDAQ: NRSN · Real-Time Price · USD
0.840
-0.026 (-2.96%)
At close: Mar 9, 2026, 4:00 PM EDT
0.857
+0.017 (2.00%)
After-hours: Mar 9, 2026, 4:46 PM EDT
NeuroSense Therapeutics Employees
NeuroSense Therapeutics had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$509,294
Market Cap
27.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17 | -1 | -5.56% |
| Dec 31, 2023 | 18 | 4 | 28.57% |
| Dec 31, 2022 | 14 | 3 | 27.27% |
| Dec 31, 2021 | 11 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Kyntra Bio | 225 |
| IGC Pharma | 70 |
| Lantern Pharma | 24 |
| Tempest Therapeutics | 21 |
| BriaCell Therapeutics | 16 |
| FibroBiologics | 15 |
| Hyperion DeFi | 14 |
| NovaBay Pharmaceuticals | 14 |
NRSN News
- 6 hours ago - PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference - PRNewsWire
- 19 days ago - NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS - PRNewsWire
- 4 weeks ago - NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - PRNewsWire
- 6 weeks ago - NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease - PRNewsWire
- 2 months ago - World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - PRNewsWire
- 2 months ago - NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study - PRNewsWire
- 3 months ago - NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 - PRNewsWire
- 3 months ago - NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS - PRNewsWire